

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>	<i>Complete if Known</i> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;">Application Number</td> <td>10/048,072</td> </tr> <tr> <td>Filing Date</td> <td>January 25, 2002</td> </tr> <tr> <td>First Named Inventor</td> <td>Franchini, Genoveffa</td> </tr> <tr> <td>Group Art Unit</td> <td>1648</td> </tr> <tr> <td>Examiner Name</td> <td>Parkin, Jeffrey</td> </tr> </table>	Application Number	10/048,072	Filing Date	January 25, 2002	First Named Inventor	Franchini, Genoveffa	Group Art Unit	1648	Examiner Name	Parkin, Jeffrey
Application Number	10/048,072										
Filing Date	January 25, 2002										
First Named Inventor	Franchini, Genoveffa										
Group Art Unit	1648										
Examiner Name	Parkin, Jeffrey										
Sheet 1 of 2	Attorney Docket No: 1662.018US1										

US PATENT DOCUMENTS				
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
	WO-0108702A3	02/08/2001	Franchini, Genoveffa , et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		"International Application Serial No. 00953728.3 (Atty Ref 1662.018EP1), Office Action mailed 04-28-05", 3 pgs		
		"International Application Serial No. 00953728.3 (Atty Ref 1662.018EP1), Office Action mailed 09-03-07", 5 pgs		
		"International Application Serial No. 00953728.3 (Atty Ref 1662.018EP1), Response filed 10-11-05 to Office Action mailed 04-28-05", 9 pgs		
		"International Application Serial No. PCT/US00/20641 (Atty Ref 1662.018EP1), International Preliminary Examination Report mailed 11-28-01", 5 pgs		
		AUTRAN, B. , et al., "Therapeutic vaccines for chronic infections", <u>Science</u> , 305(5681), (July 9, 2004),205-8		
		DORRELL, L. , et al., "Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine", <u>J Virol.</u> , 80(10), (May, 2006),4705-16		
		JOHN, M. , et al., "Control of HIV Replication by Cytotoxic T-Lymphocyte responses", <u>Journal of HIV Therapy</u> , 4(4), (1999),91-97		
		KINLOCH-DE LOES, S. , et al., "pact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.", <u>J Infect Dis.</u> , 192(4), (Aug. 15, 2005),607-17		
		MWAU, M. , et al., "A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans", <u>J Gen Virol.</u> , 85(Pt 4), (Apr., 2004),911-9		
		PAOLETTI, E. , et al., "Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC", <u>Dev Biol Stand.</u> , 84, (1995),159-163		
		PIALOUX, G. , et al., "A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA", <u>AIDS Res Hum Retroviruses.</u> , 11(3), (1995),373-381		
		ROSENWIRTH, B. , et al., "An anti-HIV strategy combining chemotherapy and therapeutic vaccination", <u>J Med Primatol.</u> , 28(4-5), (1999),195-205		

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>	Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;">Application Number</td> <td>10/048,072</td> </tr> <tr> <td>Filing Date</td> <td>January 25, 2002</td> </tr> <tr> <td>First Named Inventor</td> <td>Franchini, Genoveffa</td> </tr> <tr> <td>Group Art Unit</td> <td>1648</td> </tr> <tr> <td>Examiner Name</td> <td>Parkin, Jeffrey</td> </tr> </table>	Application Number	10/048,072	Filing Date	January 25, 2002	First Named Inventor	Franchini, Genoveffa	Group Art Unit	1648	Examiner Name	Parkin, Jeffrey
Application Number	10/048,072										
Filing Date	January 25, 2002										
First Named Inventor	Franchini, Genoveffa										
Group Art Unit	1648										
Examiner Name	Parkin, Jeffrey										
Sheet 2 of 2	Attorney Docket No: 1662.018US1										

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		TUBIANA, R. , et al., "Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).", <u>Vaccine</u> , 23(34), (July 29, 2005),4292-301	

EXAMINER

DATE CONSIDERED